publications which actually present such data. To date, the effiacy of different palliative regimens has largly been judged by resonse to treatment, s l time, toxicity and performance status (Minet et al., 1987; Thatcher et al., 1987; Cullen et al., 1988; Ferandez et al., 1989) . Performance status has been used as a proxy measure of QL, but as such is an inadequate measure because of its unidimensional nature. Its use has proved controversial, because of reported insenstivity to change with worsening toxicity (Geddes et al., 1990) and poor correlation with both psychosocial well-being (Schipper et al., 1984) and symptom prevalec (Mor et al., 1984) . Surprisingly, relief of key hlng ancer symptoms (shortness of breath, cough, chest pain and haemoptysis) has not been routinely reported, although these form the basis for intervention. Thus, in a review of trials for non-small-cell lung cancer conducted by the Easten Cooperative Oncology Group involving 3000 patients, no mention of symptoms was made, although the paper addr the issue of risks and benefits in cinical trials and endorsed the importance of quality of survival (Simes, 1985) .
Most studies of symptoms have been carTied out in the tminal care setting, in heterogeneous cancer patient groups and have focused on problems such as pain, which has been reported as the commonest symptom in advanced caer (Curtis et al., 1991) , although recently the disruptive effect of general symptoms was highlighted in a study of women with lung cancer (Sama, 1993) . More speifically, Krech et al. (1992) (Kaasa et al., 1989; Muers and Round, 1993) , while malaise and anorexia may be indicators of a poor prognosis (Muers and Round, 1993) . Such data should be generated by patients themselves however, since obsrms' opinions have been shown to be different from those of patiets (Osoba, 1994 The symptoms assessed were included in a patient selfreport measure of QL, the Rotterdam Symptom Checklist (RSCL), which has been used as an integral part of the data collection in such trials. The RSCL is a patient-completed questionnaire containing a core of 30 symptoms covering a number of domains (physical, psychological and sexual), to' which five items had been added: four symptoms specific to lung cancer (cough. haemoptysis, chest pain and hoarseness) and one further item (restlessness), which was being tested as a component of the psychological subscale (Frith, 1992) . Eight additional questions relating to activities of daily living were also routinely completed. but this subscale has not been included in this analysis. Patients completed the RSCL according to how they were feeling during the previous week, and in both trials the questionnaire was first administered at the time of randomisation. but before any treatment had been given. The full QL analyses for each trial, including explorations of the changes over time, will be reported elsewhere.
Results
In LU12 (SCLC), 232 (75%) of the 310 patients completed an RSCL questionnaire at the time of randomisation, and in LU13 (NSCLC). 423 (83%) of the 509 patients. The prevalence and severity of the reported symptoms in LU12 are shown in Figure 1 in decreasing order of prevalence. Figure 2 shows the prevalence and severity of symptoms for LU13 in the same order as Figure 1 .
The overall pattern of symptom prevalence was very similar for the two disease groups, the only major differences being the higher levels of chest pain and coughing up blood reported in LU13. Apart from chest pain, which ranked sixth in LU13 and 20th in LU12, the eight commonest symptoms in both patient groups were the same. and no clear patterns of differences between the various domains were observed.
Discon
Although the prevalence of specific symptoms will differ according to the instrument used, and by whom it is completed, one would expect to see similar patterns emerge overall. However, our data, based on a patient self-report scale, included more psychological symptoms -worry. anxiety. tension and despondency about the future -than the study reported by Krech et al. (1992) (Hopwood, 1992) . There was similanrty with Krech et al.'s data in the incidence of five physical symptoms, but, whereas pain was their most frequently observed symptom, it was not among the ten most prevalent in our analysis suggesting a difference in both patient samples and observer-patient perceptions of symptoms. With respect to gender. the increased reporting of psychological symptoms in women with NSCLC was not unexpected, since it is known that there is a higher prevalence of psychological illness in women than in men, and this accounted for much of the difference in overall number of symptoms in the trial. Surprisingly, this finding was not repeated in the SCLC trial. Curtis et al. (1991) failed to find an effect of gender on the overall number of symptoms in their small heterogeneous cancer sample, but our inconsistent findings in two large homogeneous groups suggest that it may be unwise to generalise results based on small numbers of patients with differing cancer sites. Nevertheless, our observation that the pattern of symptom prevalence was constant across patients with different performance status means that the need to take a broad approach has general application.
The prevalence of key physical symptoms in our sample of patients with NSCLC is comparable with that reported by Muers and Round (1993) using a similar assessment method, but in considering only physical indices (and excluding tiredness and lack of energy) they address only one aspect of palliation. Greater importance of chest symptoms is inevitably inferred by this method of presenting data, yet the outcome of treatment can be described by a variety of different QL end points (physical, functional, psychosocial), which may, in turn, give conflicting information (Earl et al., 1991; Richards et al., 1992; Holl and Hakama, 1993) .
Clearly, while disease-related symptoms are a necessary focus for anti-cancer therapy, and their palliation an indicator of the success of the therapy, there are other important symptoms and markers of psychological distress that should cause concern and alert health professionals to the need for intervention (e.g. psychological support). One important aspect of QL research is to increase awareness of the variety of symptoms reqiiring treatment, especially in the palliative setting. Little is yet known about the relative impact on the patient of specific symptoms such as fatigue (which may seriously compromise function) or haemoptysis (which may cause considerable alarm and signify active disease) or the way in which symptoms interact (e.g. palhating cough may also decrease anxiety and worry). Other issues also warrant further research, such as assessing clinically meaningful changes from questionnaire data and distinguishing effects of treatment on QL from those attributable to the disease.
In our sample, the ranking of the top four symptoms remained unchanged when a second cross-section of the data was examined I month before death. Longitudinal analyses will inform us of the extent of palliation and change in severity of symptoms over time, but these data suggest that pretreatment symptoms are an important indicator of aspects of well-being that will require continued assessment and intervention.
The implications for the evaluation of new treatments designed to palliate lung cancer is that a much wider range of symptoms need to be assessed and monitored before treatments can be claimed to provide effective palliation. Knowledge of symptom profiles and patterns of change may help health care professionals prevent as well as relieve distress, and provide optimum palliative care.
